Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Merck & Co., Inc. and Lundbeck Announce Update in Submission Plans for U.S. Approval of Gaboxadol
- WHITEHOUSE STATION, N.J. & COPENHAGEN, Denmark -- Merck & Co., Inc., Whitehouse Station, N. J., U.S.A. and H. Lundbeck A/S of Denmark today announced that submission of a New Drug Application NDA for gaboxadol with the U.S. Food and Drug Administration will no longer occur in the first quarter of...
- Research articles 2006-10-13
- Pfizer drug no threat to Cipramil, says Lundbeck
- NORDIC BUSINESS REPORT-6 June 2002-Pfizer drug no threat to Cipramil, says Lundbeck C1994-2002 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2002-06-06
- Suit vs. Forest Labs Names Execs Linked to Alleged Lies About Lexapro, Celexa
- Employees of Forest Labs and that company's rivals should read the U.S. government's complaint against the company, which alleges off-label promotion of Lexapro and Celexa for use in children. The complaint names executives, indicates who knew what and when, and goes into the details of many individual sales reps' actions....
- Blog posts 2009-02-26
Additional Resources
- Lundbeck's epilepsy med approved, J&J's rejected
- Shares of Lundbeck are on the rise today on the news that the FDA has approved the drugmaker's anti-epilepsy drug Sabril. The drug, which received the FDA nod as a monotherapy on Friday, is the first approved for the treatment of infantile spasms in children aged one month to two...
- News items 2009-08-24
- Danish pharmaceutical company H Lundbeck A/S signs cooperation agreement with Japan's Takeda Pharmaceutical Company Limited
- NORDIC BUSINESS REPORT-5 September 2007-Danish pharmaceutical company H Lundbeck A/S signs cooperation agreement with Japan's Takeda Pharmaceutical Company LimitedC1994-2007 M2 COMMUNICATIONS LTD http://www.m2.com Danish pharmaceutical company H Lundbeck A/S announced on Wednesday (5 September) a strategic alliance with Japan's Takeda Pharmaceutical Company Limited. The companies will cooperate in...
- Research articles 2007-09-05
- Lundbeck's Late Stage Pipeline Keeps Looking Thinner
- EP Vantage submits: Lundbeck (HLUKY.PK) yesterday announced yet another setback to its late-stage pipeline, with the news that it and partner Solvay (SVYSY.PK) would be discontinuing development of anti-psychotic drug bifeprunox. While the news itself was not a massive surprise following an earlier failure of the drug as...
- External links 2009-07-31
- Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO® Patent Litigation
- NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, "Forest"), and H. Lundbeck A/S ("Lundbeck") announced today that they have entered into a settlement agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma", a reference that...
- Research articles 2009-07-10
- Merck & Co., Inc. and Lundbeck Discontinue Joint Development Program for Gaboxadol, an Investigational Compound for Insomnia
- WHITEHOUSE STATION, N.J. & COPENHAGEN, Denmark -- Merck & Co., Inc., and H. Lundbeck A/S announced today the discontinuation of their joint development program for gaboxadol, an investigational new medicine for the treatment of insomnia currently in Phase III development. Data from recently completed clinical studies suggest that the overall...
- Research articles 2007-03-28
- Lundbeck and Merck Announce Extension to Japan of Alliance to Develop and Commercialize Gaboxadol
- COPENHAGEN, Denmark & WHITEHOUSE STATION, N.J. -- H. Lundbeck A/S and Merck & Co., Inc. today announced an extension of their agreement for the exclusive development and commercialization of sleep disorder compound gaboxadol to Japan.
- Research articles 2004-06-28
- H Lundbeck A/S's gaboxadol commercialisation deal with Merck & Co Inc could create up to 1,000 new jobs - report
- NORDIC BUSINESS REPORT-11 February 2004-H Lundbeck A/S's gaboxadol commercialisation deal with Merck & Co Inc could create up to 1,000 new jobs - reportC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2004-02-11
- H Lundbeck A/S and Merck & Co Inc expand cooperation to Japan
- NORDIC BUSINESS REPORT-28 June 2004-H Lundbeck A/S and Merck & Co Inc expand cooperation to JapanC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2004-06-28
- H Lundbeck A/S signs cooperation agreement with Merck & Co Inc
- NORDIC BUSINESS REPORT-10 February 2004-H Lundbeck A/S signs cooperation agreement with Merck & Co IncC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2004-02-10
- Forest and Lundbeck file lawsuit against Caraco for patent infringement.
- Forest Laboratories, Inc. (New York, NY), Forest Laboratories Holdings, Ltd. and H. Lundbeck A/S announced that they have filed a lawsuit in the United States District Court for the Eastern District of Michigan against Caraco Pharmaceutical Laboratories, Ltd. for infringement of United States Patent Re. No....
- Research articles 2006-06-01
- How to Lose $100 Million in 40 Days
- The failure of Myriad Genetics' experimental Alzheimer's drug Flurizan is surely unfortunate news for those with the disease and their families, but it also reflects badly on the Danish pharma H. Lundbeck, which paid Myriad $100 million on May 22 for European rights to the drug. Since Myriad has discontinued...
- Blog posts 2008-07-01
- Forest Lab's Hard Sell of Anti-Depressant Raises Questions
- Derek Lowe submits: Forest Labs FRX has done very, very well with Lexapro escitalopram over the years. They're a comparatively small company, and their collaboration with Lundbeck (HLUKY.PK) also a comparatively small company in the antidepressant field has been the biggest event in their history. Lexapro...
- External links 2009-09-02
- Leading Pharmaceutical Company, Lundbeck Australia, Deploys Centra Web Collaboration Platform for Critical Drug Training Initiatives
- Business/Technology Editors & Health/Medical Writers
- Research articles 2002-09-05
- IMS HEALTH Strategic Technologies Signs Lundbeck Hellas in Greece for Its Premiere Pharmaceutical Relationship Management Solution
- LONDON--BW HealthWire--December 17, 1999--
- Research articles 1999-12-17
- Ims Health Strategic Technologies Signs Lundbeck In Germany For Its Premiere And Pharbase Pharmaceutical Relationship Management Solutions
- LONDON--BW HealthWire--December 8, 1999--
- Research articles 1999-12-08
- Biovail Completes Development of New Celexa Formulation; Lundbeck to Initiate Phase III Studies
- Business Editors, Health/Medical Writers
- Research articles 2000-06-29
- CEPHALON Inc.
- CEPHALON Inc.'s second quarter revenues totaled $10.7 million, up from $3.4 million in the same period last year. Revenues were driven ... CEPHALON Inc.'s second quarter revenues totaled $10.7 million, up from $3.4 million in the same period last year. Revenues were driven ...
- Research articles 1999-08-16
- << Previous
- page 1 of 1
- Next >>
Presented by American Express